Medicenna Therapeutics (MDNA.F) Stock Overview

A clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. More details

MDNA.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (CA$0)

Earnings are forecast to decline by an average of 0.3% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

MDNA.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW485,257 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

485,257 investors already sharing narratives

View all narratives

Medicenna Therapeutics Corp. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Medicenna Therapeutics
Historical stock prices
Current Share Price	CA$0.25
52 Week High	CA$1.43
52 Week Low	CA$0.25
Beta	1.89
1 Month Change	-13.29%
3 Month Change	-44.40%
1 Year Change	-60.62%
3 Year Change	-40.20%
5 Year Change	-88.88%
Change since IPO	-83.21%

Recent updates

Seeking Alpha • Sep 30

Medicenna extends period to exercise certain warrants

Medicenna Therapeutics (NASDAQ:MDNA) received conditional approval from the TSX to extend the expiry date of the common share purchase warrants of the company originally issued on October 17, 2019. The warrants, of which 1,549,052 are available to be extended, are exercisable for common shares of the company at a price of $1.75/common share and are set to expire on October 17, 2022, will now expire on July 17, 2023, an extension of 9 months. All other terms of the warrants, including the exercise price, remain unchanged. There are 1,661,552 warrants remaining available for exercise including 112,500 warrants held directly or indirectly by insiders of the company which will not be extended.

Seeking Alpha • Sep 13

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Medicenna Therapeutics (NASDAQ:MDNA) on Tuesday said it had entered into a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate its agonist in combination with cancer drug Keytruda in its ongoing phase 1/2 study named ABILITY. Medicenna's (MDNA) agonist, MDNA11, is being assessed in the early- to mid-stage trial as a monotherapy and in combination with MRK's Keytruda to treat patients with cancerous tumors. As per the clinical trial collaboration deal, MDNA will sponsor the study and MRK will supply Keytruda. "Although we believe that MDNA11 has great potential as a single agent, combining it with Keytruda may significantly enhance therapeutic benefit in different types of cancer, potentially maximizing the value of MDNA11," MDNA CEO Fahar Merchant said in a statement. MDNA stock +1.5% to $1.03 in afternoon trading.

Seeking Alpha • Aug 15

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics press release (NASDAQ:MDNA): Q1 GAAP EPS of -$0.07 in-line. Medicenna had cash, cash equivalents, and marketable securities of $19.3 million at June 30, 2022, compared to $20.5 million at March 31, 2022.

Seeking Alpha • Aug 08

Medicenna Therapeutics stock slides on launch of units offering

Medicenna Therapeutics (NASDAQ:MDNA) shares fell 6% in Monday's extended session after the immunotherapy company announced the launch of an underwritten public offering of units in the U.S. Each unit will be comprised of one common share and one warrant to purchase common shares. The offering is expected to be priced in the context of the market, with the final terms to be determined at the time of pricing. The company plans to use the net proceeds primarily to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, working capital and for general corporate purposes.

Shareholder Returns

	MDNA.F	US Biotechs	US Market
7D	-6.2%	-3.6%	-0.9%
1Y	-60.6%	33.3%	19.1%

Return vs Industry: MDNA.F underperformed the US Biotechs industry which returned 32.8% over the past year.

Return vs Market: MDNA.F underperformed the US Market which returned 20.5% over the past year.

Price Volatility

Is MDNA.F's price volatile compared to industry and market?
MDNA.F volatility
MDNA.F Average Weekly Movement	10.5%
Biotechs Industry Average Movement	10.3%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: MDNA.F has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MDNA.F's weekly volatility (10%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	15	Fahar Merchant	www.medicenna.com

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer.

Medicenna Therapeutics Corp. Fundamentals Summary

How do Medicenna Therapeutics's earnings and revenue compare to its market cap?
MDNA.F fundamental statistics
Market cap	US$23.98m
Earnings (TTM)	-US$13.10m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.8x

P/E Ratio

Is MDNA.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDNA.F income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$18.41m
Earnings	-CA$18.41m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.20
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did MDNA.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/16 04:12
End of Day Share Price	2026/07/16 00:00
Earnings	2026/03/31
Annual Earnings	2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicenna Therapeutics Corp. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Charles Zhu	Guggenheim Securities, LLC
Swayampakula Ramakanth	H.C. Wainwright & Co.
Dev Prasad	Lucid Capital Markets

Medicenna Therapeutics (MDNA.F) Stock Overview

Risk Analysis

Join community and earn perks

Medicenna Therapeutics Corp. Competitors

CEL-SCI

Skye Bioscience

Akari Therapeutics

Marker Therapeutics

Price History & Performance

Recent News & Updates

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of CAD 4.44 million.

Medicenna Therapeutics Corp. has filed a Follow-on Equity Offering.

Medicenna Therapeutics Corp Announces First Patient Dosed in Neo-Cyt Study of Mdna11 in Neoadjuvant Melanoma

Medicenna Therapeutics Corp Announces Presentation Of NEOCYT Trial At ASCO

Medicenna Therapeutics Corp Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of Its First-In-Class Anti-Pd-1 X Il-2 Bifunctional Superkine Mdna113 At Aacr

Medicenna Therapeutics Corp. Appoints Nageatte Ibrahim as Chief Medical Officer

Recent updates

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of CAD 4.44 million.

Medicenna Therapeutics Corp. has filed a Follow-on Equity Offering.

Medicenna Therapeutics Corp Announces First Patient Dosed in Neo-Cyt Study of Mdna11 in Neoadjuvant Melanoma

Medicenna Therapeutics Corp Announces Presentation Of NEOCYT Trial At ASCO

Medicenna Therapeutics Corp Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of Its First-In-Class Anti-Pd-1 X Il-2 Bifunctional Superkine Mdna113 At Aacr

Medicenna Therapeutics Corp. Appoints Nageatte Ibrahim as Chief Medical Officer

Medicenna Therapeutics Corp Presents Preclinical Data for Mdna113 Bifunctional Superkine

Medicenna Therapeutics Corp. Announces Board Changes, Effective February 12, 2026

Medicenna Therapeutics Corp. Announces Key Program Updates and 2026 Outlook

Medicenna Therapeutics Corp. Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, “NEO-CYT”, in High-Risk, Surgically Resectable Stage III Melanoma

Medicenna Therapeutics Corp. Announces John H. Sampson Not Standing for Re-Election

Medicenna Therapeutics Corp., Annual General Meeting, Sep 25, 2025

Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting

Medicenna Therapeutics Corp. Reports Mdna11's Compelling Anti-Cancer Activity Is Associated with Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells At the Inaugural Aacr-Oncology Conference and Provides Ability-Oncology Study Update

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium

Medicenna Therapeutics Corp Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA®? (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Medicenna Therapeutics Corp. Announces Updated Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Therapeutics Corp. Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

Price target decreased by 8.9% to US$5.83

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

High number of new and inexperienced directors

Lead Independent Director recently bought US$54k worth of stock

Medicenna extends period to exercise certain warrants

Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment

Price target decreased to US$7.00

Medicenna Therapeutics GAAP EPS of -$0.07 in-line

Medicenna Therapeutics stock slides on launch of units offering

No longer forecast to breakeven

Price target decreased to US$8.40

Price target increased to US$10.50

High number of new and inexperienced directors

Forecast to breakeven in 2025